.Pharmacolibrary.Drugs.R_RespiratorySystem.R03D_OtherSystemicDrugsForObstructiveAirwayDiseases.R03DX09_Mepolizumab.Mepolizumab .Pharmacolibrary.Drugs.R_RespiratorySystem.R03D_OtherSystemicDrugsForObstructiveAirwayDiseases.R03DX09_Mepolizumab.Mepolizumab| name: | Mepolizumab | |
| ATC code: | R03DX09 | route: | subcutaneous |
| compartments: | 2 | |
| dosage: | 100 | mg |
| volume of distribution: | 3.6 | L |
| clearance: | 0.283 | L/day |
| other parameters in model implementation | ||
Mepolizumab is a humanized monoclonal antibody that targets interleukin-5 (IL-5), used as an add-on maintenance treatment for severe eosinophilic asthma and hypereosinophilic syndrome. It is approved by major regulatory agencies including FDA and EMA.
Pharmacokinetics reported in adult patients with severe eosinophilic asthma; data based on population pharmacokinetic analysis from clinical trials.
Poulakos, MN, et al., & Wolford, AL (2017). Mepolizumab for the treatment of severe eosinophilic asthma. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 74(13) 963–969. DOI:10.2146/ajhp160291 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28645995